Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study.

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Cabometyx (cabozantinib tablet) - Exelixis

Inlyta (axitinib) - Pfizer

Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study. (PubMed, Res Rep Urol) - Oct 20, 2026 - "Given the small exploratory cohort, no firm conclusion regarding the comparative efficacy of the two sequences can be drawn. Patients with early PD showed a numerical trend toward shorter combined TTF, although this comparison was statistically inconclusive."
Clinical data • Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42894711

Akari Kataoka; Nobuki Furubayashi; Takahito Negishi; Takehito Kojima; Yasuhiro Nakano

Oct 20, 2026